Launching techMATCH for your ideas: Champion intraocular therapy drug delivery systems
06 May 2024
The visual impairment caused by various diseases significantly impacts the quality of patients` life. The eye is a very sensitive organ with a sophisticated physiology and is composed of anterior and posterior segments. Especially the administration of drugs into the posterior segment is a treatment which causes pain, leads to patient non-compliance, has risks of infection, and is associated with various side effects. To obtain a constant level of drug substance the applications are often repeated with a weekly frequency.
Boehringer Ingelheim is dedicated to develop innovative drug delivery concepts that go far beyond current solutions. With our current opnMe call, we invite you to propose concepts with breakthrough potential in the challenging field of intraocular drug delivery:
How would you propose to progress intraocular drug delivery systems for the posterior segment that ensure sustained release over at least three months for diverse therapeutic modalities?
Eligible solutions may come from scientists with very different backgrounds, ranging from academia, start-ups, biotech, or even larger enterprises such as device or pharmaceutical companies. By participating, you have a unique chance to push the boundaries and make a significant impact in the field of drug delivery devices. You will benefit by collaborating directly with the cross-functional experts of the Device Development team of Boehringer Ingelheim.
In case your proposal has been selected, you can expect sufficient monetary funding to progress your conceptual ideas towards clinical readiness by collaborating with the cross-functional experts of the Device Development team of Boehringer Ingelheim. Beyond funding, which will be negotiated with the selected partners in good faith, we offer support in engineering capabilities for design reviews, including a strong connection to patient insights, prototyping or pharmacokinetics studies with a range of relevant molecules.
Apply soon as your proposals can only be accepted if they arrive by July 9, 2024, 11:59 pm PST.
No registration required for download
Subscribe to our newsletter to stay updated as we add new molecules or calls to opnMe.com.
About our techMATCH question:
How would you propose to progress intraocular drug delivery systems for the posterior segment that ensure sustained release over at least three months for diverse therapeutic modalities? With ambitious questions such as this, we share precisely formulated technological questions with the expert community on opnMe. We welcome game-changing ideas from academia, startups, biotech, and larger corporations.
About opnMe:
opnMe.com, the open innovation portal of Boehringer Ingelheim, aims to accelerate research initiatives to enable new insights of disease biology in areas of high unmet medical need by sharing well-characterized molecules and offer collaborations for science. Our molecules are either freely available as “Molecules to Order” or offered as part of “Molecules for Collaboration” program calls. Interested scientists are invited to submit testable research hypotheses with these assets in novel diseases or combinations. With our “opn2EXPERTS” program, we enlist advice on key scientific issues to fuel further drug discovery and pharmacology, while “techMATCH” focuses on technology topics.